GenSight Biologics Archives

In Depth 11 Jun 2025

Can gene therapy treat vision loss?

Since the approval of Luxturna, there has been a wave of companies developing treatments with the potential to cure different forms of genetic blindness.

June 11, 2025 - 12 minutesmins - By Roohi Mariam Peter

Best in Biotech 4 Nov 2022

Get to know 15 of the best biotech companies in Paris

Paris may attract tourist masses, but it also attracts a lot of biotech enthusiasts. In this guide, we explore 15 interesting biotech companies in Paris. Paris is one of the biggest biotech clusters in Europe, with a wide range of applications being developed from drug discovery and medical devices to synthetic biology and green energy. […]

November 4, 2022 - 11 minutesmins - By Omnia Ibrahim

More News! 17 Oct 2019

Sofinnova Partners Raises €333M for its Newest Life Sciences-Focused Fund

Sofinnova Partners, Europe’s largest VC focused on life sciences, has raised €333M to fund early-stage healthcare companies, bringing the total capital managed by the firm to €2B. Sofinnova Partners aims to invest around two-thirds of the new fund, called Sofinnova Capital IX, in European life science companies. The other third will be invested globally, with […]

October 17, 2019 - 2 minutesmins - By Jonathan Smith

gensight gene therapy lhon genetic blindness

News and Trends 29 May 2019

After Unexpected Setback, GenSight Seeks Approval for Blindness Gene Therapy

The French biotech GenSight will apply for regulatory approval for its gene therapy despite the treatment unexpectedly resulting in the improvement of the eyes treated with a placebo in a phase III trial. GenSight is developing a gene therapy designed to treat progressive vision loss caused by the rare genetic condition Leber hereditary optic neuropathy. […]

May 29, 2019 - 2 minutesmins - By Jonathan Smith

genesight gene therapy blindness placebo

News and Trends 4 Apr 2018

Placebo Beats a Gene Therapy for Blindness in a Phase 3 Trial

GenSight has demonstrated that its gene therapy for a rare disease causing blindness can significantly improve the vision of patients. But so does the placebo. GenSight Biologics has released the results of a Phase III clinical trial testing its gene therapy GS010 in patients suffering from Leber hereditary optic neuropathy (LHON), a rare mitochondrial disease […]

April 4, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 20 Feb 2018

This Gene Therapy for Vision Loss is Safe and Effective After Two Years

The results of a long-term follow-up suggest that GenSight’s gene therapy for Leber hereditary optic neuropathy can provide safe and effective treatment for the genetic cause of vision loss. GenSight develops gene therapies to preserve or restore vision in patients with neurodegenerative diseases of the retina. The biotech’s lead candidate is GS010, which is currently […]

February 20, 2018 - 3 minutesmins - By Alex Dale

gensight retinitis pigmentosa gene therapy

News and Trends 10 Jan 2018

French Biotech Starts Trials to Restore Sight in All Types of Retinitis Pigmentosa

GenSight will start a clinical trial in the UK testing a combination of gene therapy and a wearable device to restore sight in patients with retinitis pigmentosa. The UK Medicines and Healthcare Regulatory Agency (MHRA) has accepted GenSight’s application to run a first clinical trial in the UK testing a new type of therapy with the […]

January 10, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

Best in Biotech 18 Dec 2017

Smile! Here are the 12 Biggest Biotech Clinical Successes of 2017

Now that we’ve got the bad news out of the way, we’re here to spread some Christmas cheer with the biggest clinical successes in biotech over the past 12 months. It’s unlikely that one whole year will ever pass without a single hiccup, especially in a field as complex as biotech. For that reason, we […]

December 18, 2017 - 9 minutesmins - By Alex Dale

GeneSight eye gene therapy sight restoration

News and Trends 5 Dec 2017

Update: French Gene Therapy Yields Longer Term Sight Restoration, Eyes Phase III

Update (05/12/2017): GenSight has reported a sustained effect of its treatment GS010, which has now been shown to restore sight in patients for at least 2.5 years after administration. Phase III results for the candidate are expected next year. Originally published 14/06/2017 GenSight has announced Phase I/II data revealing that its gene therapy technology can […]

December 5, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

In Depth 28 Nov 2017

Reviewing Gene Therapy: How Close is Biotech to Genetic Cures?

Over 10,000 human diseases are caused by exactly one faulty gene. Gene therapy promises to fix each of them. Here’s a review of biotech’s progress. Biotech is arguably built on genetic medicine. When Genentech‘s insulin produced by genetically engineered bacteria kicked off biotech fever in the 1980s, the concept of directly repairing defective human DNA wasn’t […]

November 28, 2017 - 8 minutesmins - By Evelyn Warner

More News! 23 Jun 2017

French Biotech Raises Over €22M to Launch a Gene Therapy to Restore Sight

Gensight Biologics has announced a capital increase that totals €22.5M and will support the launch of its gene therapy for blindness in Europe and the US. Gensight has decided to give an additional financial push to its lead candidate, GS010, a gene therapy to restore sight in patients with the rare genetic disease Leber hereditary optic […]

June 23, 2017 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 26 Dec 2016

The Largest Deals, Fundraising and Exits of 2016 in European Biotech

Curious about which technologies have attracted the most cash in biotech finance this year? Here’s a list of the most impressive cash movements of 2016 in Europe. Believe it or not, 2016 has been the worst year for biotech finance in a decade. The political scene has become unfavorable for British biotech after Brexit, and the uncertainty raised by […]

December 26, 2016 - 5 minutesmins - By Clara Rodríguez Fernández

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

GenSight Biologics

Can gene therapy treat vision loss?

Get to know 15 of the best biotech companies in Paris

Sofinnova Partners Raises €333M for its Newest Life Sciences-Focused Fund

After Unexpected Setback, GenSight Seeks Approval for Blindness Gene Therapy

Placebo Beats a Gene Therapy for Blindness in a Phase 3 Trial

This Gene Therapy for Vision Loss is Safe and Effective After Two Years

French Biotech Starts Trials to Restore Sight in All Types of Retinitis Pigmentosa

Smile! Here are the 12 Biggest Biotech Clinical Successes of 2017

Update: French Gene Therapy Yields Longer Term Sight Restoration, Eyes Phase III

Reviewing Gene Therapy: How Close is Biotech to Genetic Cures?

French Biotech Raises Over €22M to Launch a Gene Therapy to Restore Sight

The Largest Deals, Fundraising and Exits of 2016 in European Biotech

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!